Browsing Tag
Becton Dickinson and Company
7 posts
Why did Becton Dickinson appoint Vitor Roque as interim CFO, and what’s next for BDX stock?
Becton Dickinson (NYSE: BDX) names Vitor Roque as interim CFO as Christopher DelOrefice exits. Find out what this means for BDX’s strategy and investor sentiment.
Could Waters’ execution playbook unlock BD’s underperforming diagnostics margins?
Can Waters fix BD’s diagnostic margins post-merger? Learn how service plans, e-commerce, and faster instrument cycles could transform its revenue profile.
What does BD gain from the $4bn cash windfall—and how fast will buybacks follow the spin?
BD’s $4B cash windfall from the Waters merger could reshape its capital strategy. Will buybacks come first, or will growth investments take priority?
Can Waters bring LC-MS into routine diagnostics with BD’s hospital channel access?
Can Waters bring LC-MS to hospitals through its $17.5B BD merger? Find out how this deal could redefine clinical mass spectrometry adoption in diagnostics.
Why did Waters stock fall 12% after the merger announcement—and are investors overreacting to leverage risk?
Waters stock fell 12% after its $17.5B merger news with BD—find out why investors reacted sharply and what could reverse the slide in coming quarters.
BD to merge biosciences and diagnostics unit with Waters in $17.5bn tax-free deal
Waters to merge with BD’s biosciences and diagnostics unit in a $17.5B deal. Explore how the combined firm plans to reshape regulated testing markets.
Wall Street rout: Top U.S. stock losers on May 1 reflect deep-sector woes, policy shocks, and earnings misses
Discover how major U.S. companies like Eli Lilly and Becton Dickinson are navigating stock declines amid economic and industry challenges.